Affiliation:
1. Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Russian Medical Academy of Continuing Professional Education
2. Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Russian Medical Academy of Continuing Professional Education; Irkutsk Regional Psychoneurologic Dispensary
3. Irkutsk Regional Psychiatric Hospital N 1
Abstract
Background. The use of atypical antipsychotics in schizophrenia contributes to the reduction of psychotic, affective, negative and cognitive disorders.Aims. To evaluate the effectiveness of ziprasidone therapy in patients with schizoaffective disorder and paranoid schizophrenia with episodic course.Materials and methods. In accordance with ICD-10 there were 14 (63.6 %) people with schizoaffective disorder (F25), 8 (36.4 %) people with paranoid schizophrenia, episodic course (F20.x1). Treatment with ziprasidone lasted 42 days. The dose of ziprasidone in 6 patients (27.3 %) was 80 mg, in 10 patients (45.5 %) – 120 mg, in 6 patients (27.3 %) – 160 mg. Evaluation of the effectiveness of ziprasidone therapy was carried out using psychometric scales (PANSS, General clinical impression scale to assess the effectiveness of therapy – CGI-S, CGI-I), adverse events were registered with the UKU scale.Results. The number of respondents was 19 (86.3 %) (reduction of the total score on the PANSS scale > 20 % of the pre-treatment level). Ziprasidone was effective in patients with schizoaffective disorder with a significant decrease in total score on PANSS subscales to the 14 th day of therapy (p < 0.05), with paranoid schizophrenia with episodic course – by the 21st day (p < 0.01). According to the CGI-S scale at the end of therapy, “borderline condition” was observed in 10 patients (52.6 %), mild severity – in 3 (15.8 %), normal condition – in 6 (31.6 %). CGI-I scale showed a significant improvement in 10 patients (52.6 %), marked improvement – in 9 patients (47.4 %). Among the mild adverse events that do not require discontinuation of the drug, we noted: weakness – in 3 patients (15.8 %), drowsiness – in 3 (15.8 %), impaired concentration – in 2 (10.5 %), orthostatic dizziness – in 2 (10.5 %), galactorrhea – in 1 (5.3 %).Conclusions. Ziprasidone is an effective antipsychotic drug that has a safe tolerability profile. It can be used in patients with schizoaffective disorders and paranoid schizophrenia with episodic course.
Reference10 articles.
1. Mosolov SN. Biological methods of therapy of mental disorders (evidence-based medicine – to clinical practice).M.: BINOM; 2012. (In Russ.)
2. Wilson M, Pepper D, Currier G. Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting. J Emerg Med. 2013; 45(6): 901-908. doi: 10.1016/j.jemermed.2013.07.020
3. Morozov PV. Zeldox (ziprasidone) – a new atypical neuroleptic. Psikhiatriya i psikhofarmakoterapiya. 2005; 7(5): 264-268. (In Russ.)
4. Medvedev VE, Syunyakov TS. Ziprasidone for intramuscular administration: experience and possibilities of application in psychiatry. Sovremennaya terapiya psikhicheskikh rasstroistv. 2017; 1: 45-52. doi: 10.21265/PSYPH.2017.40.4987 (In Russ.)
5. Kaengkan P, Baek SE, Kim JY, Kam KY, Do BR, Lee ES, Kang SG. Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of ischemic brain damage in rats. Mol Cells. 2013; 36(6): 534-541. doi: 10.1007/s10059-013-0235-2